# MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) hires MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) (Pharmacy, Medicare/Medicaid)

**Score:** 60/100

| Field | Value |
|---|---|
| Client | MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) |
| Client description | Represents and protects the interests of midsized biopharmaceutical innovators. |
| Client state | DC |
| Lobbying firm | MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA) |
| Firm state | DC |
| Issue areas | Pharmacy, Medicare/Medicaid |
| Specific matters disclosed | Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues. · Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues. |
| Registered | 2026-10-19 |

## Why this score
- Lobbying on several issue areas.
- Specific matters disclosed.

Source: U.S. Senate and House Lobbying Disclosure Act (LDA) filings via lda.gov; Colorado Secretary of State, NYC City Clerk eLobbyist and City of Chicago Board of Ethics lobbying data (https://lda.gov/filings/public/filing/20b73a99-2e1a-4d1f-a66e-f30da584f404/print/). Last refreshed: 2026-11-03T19:42:41.566Z.
From public Lobbying Disclosure Act registrations (lda.gov) and Colorado, New York City and City of Chicago lobbying disclosures. Organization level only: we never list lobbyist, CEO or contact names, and clients whose name reads as a person are left out. Chicago amounts are lobbyist compensation reported for the quarter, summed by client. A registration reports intent to lobby; it is not evidence of wrongdoing.